Organon & Co. (NYSE:OGN) Receives Average Recommendation of “Hold” from Analysts

Shares of Organon & Co. (NYSE:OGN) have been given a consensus recommendation of “Hold” by the seven research firms that are covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating, three have given a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $20.80.

A number of research analysts have recently weighed in on the stock. TD Cowen raised shares of Organon & Co. to a “hold” rating in a research note on Wednesday, January 15th. Barclays lowered their target price on shares of Organon & Co. from $26.00 to $24.00 and set an “overweight” rating for the company in a research note on Friday. Finally, Morgan Stanley decreased their price target on shares of Organon & Co. from $17.00 to $16.00 and set an “equal weight” rating on the stock in a report on Friday.

Hedge Funds Weigh In On Organon & Co.

Hedge funds and other institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. boosted its stake in Organon & Co. by 0.7% during the 4th quarter. Vanguard Group Inc. now owns 30,401,709 shares of the company’s stock worth $453,593,000 after acquiring an additional 218,165 shares during the last quarter. Pacer Advisors Inc. lifted its stake in Organon & Co. by 94,482.1% in the fourth quarter. Pacer Advisors Inc. now owns 11,152,179 shares of the company’s stock valued at $166,391,000 after buying an additional 11,140,388 shares in the last quarter. Massachusetts Financial Services Co. MA lifted its stake in Organon & Co. by 1.4% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 9,895,067 shares of the company’s stock valued at $147,634,000 after buying an additional 136,760 shares in the last quarter. LSV Asset Management lifted its stake in Organon & Co. by 0.4% in the fourth quarter. LSV Asset Management now owns 7,525,076 shares of the company’s stock valued at $112,274,000 after buying an additional 30,557 shares in the last quarter. Finally, Geode Capital Management LLC lifted its stake in Organon & Co. by 0.3% in the fourth quarter. Geode Capital Management LLC now owns 4,260,218 shares of the company’s stock valued at $63,582,000 after buying an additional 12,110 shares in the last quarter. 77.43% of the stock is owned by institutional investors.

Organon & Co. Stock Performance

Shares of OGN traded down $0.66 during mid-day trading on Friday, hitting $15.66. 1,196,459 shares of the company’s stock were exchanged, compared to its average volume of 2,715,229. Organon & Co. has a fifty-two week low of $13.87 and a fifty-two week high of $23.10. The firm has a market capitalization of $4.03 billion, a P/E ratio of 3.11, a P/E/G ratio of 0.83 and a beta of 0.76. The business’s 50 day moving average is $15.34 and its two-hundred day moving average is $17.53. The company has a current ratio of 1.70, a quick ratio of 1.21 and a debt-to-equity ratio of 17.73.

Organon & Co. (NYSE:OGN) last announced its earnings results on Thursday, February 13th. The company reported $0.83 earnings per share for the quarter, missing the consensus estimate of $0.92 by ($0.09). Organon & Co. had a return on equity of 644.70% and a net margin of 20.30%. On average, equities analysts expect that Organon & Co. will post 3.82 earnings per share for the current year.

About Organon & Co.

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.